Form PTO-1390-MOD (REV 10-96)		Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER 33366-US-PCT						
TRANSMITTAL LETTER TO THE UNITED STATES			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/571,734						
DESIGNATE	10/3/1,/34								
		IDER 35 U.S.C. 371	PRIORITY DATE OF AIMED						
INTERNATIONAL APPLIC PCT/EP2004/010468	ATION NO.	INTERNATIONAL FILING DATE 17 September 2004 (17.09.04)	PRIORITY DATE CLAIMED 18 September 2003 (18.09.03)						
TITLE OF INVENTION									
COMBINATION OF A HISTONE DEACETYLASE INHIBITOR WITH A DEATH RECEPTOR LIGAND  APPLICANT(S) FOR DO/EO/US									
ATADJA ET AL.									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
<ol> <li>This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay</li> </ol>									
examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).  4.  A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority									
date.  5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))  a. is transmitted herewith (required only if not transmitted by the International Bureau).									
<ul> <li>b.  has been transmitted by the International Bureau. (See Form PCT/IB/308)</li> <li>c.  is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul>									
<ul> <li>6.  A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li>7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).</li> </ul>									
b. 🔲 have been ti	<ul> <li>a.  are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b.  have been transmitted by the International Bureau.</li> <li>c.  have not been made; however, the time limit for making such amendments has NOT expired.</li> </ul>								
d. 🔲 have not be	en made and will not								
9. An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).  10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C.									
371(c)(5)).									
Items 11. to 16. below concern document(s) or information included.									
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.									
12. An assignment docu	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
13. A FIRST preliminary  A SECOND or SUB	<ul> <li>A FIRST preliminary amendment.</li> <li>A SECOND or SUBSEQUENT preliminary amendment.</li> </ul>								
14. An Application Data	An Application Data Sheet under 37 CFR 1.76.								
15. A substitute specific	15. A substitute specification.								
16.  A change of power	☐ A change of power of attorney and/or address letter.								
17. A computer-readable	☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.								
18. A second copy of th	A second copy of the published International Application under 35 U.S.C. 154(d)(4).								
19. A second copy of th	e English language t	ranslation of the International applicat	ion under 35 U.S.C. 154(d)(4).						
20. Other items or infor	mation:								

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/571,734	<u> </u>	INTERNATIONAL APPLICATION NO. ATTORNEYS PCT/EP2004/010468 33366-U		DOCKET NUMBER S-PCT				
The following fees are submitted:	CALCULATIONS PTO USE							
21. Basic national fee								
22. Examination Fee  If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)								
All other situations								
23. Search fee  If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$  If International Search Report was prepared and provided to the Office \$  All other situations								
	\$ 0							
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
	Number of each additional 50 of thereof (round up to a whole no		RATE					
- 100 =   /50 ≈		X \$	250	\$				
Surcharge of \$130 for furnishing the oath of declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).								
CLAIMS NUMBE Total claims			TE					
Independent claims	- 20 =	X \$	50	\$				
MULTIPLE DEPENDENT CLAIM(S)		X \$ + \$	200 360	\$ \$				
	\$ 130							
TOTAL OF ABOVE CALCULATIONS =  Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).								
SUBTOTAL =								
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).								
	\$ 130							
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +								
TOTAL FEES ENCLOSED =								
				Amount to be: refunded charged	\$ 			
a. A check in the amount of \$_	to cover the a	bove fees is enclosed						
b.   Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$130 to cover the above fees. A duplicate copy of this form is enclosed.								
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
Send all correspondence to the address associated with Customer No. 001095, which is currently:								
Novartis Corporate Intellectual Propert One Health Plaza, Building 10 East Hanover, NJ 07936-1080								